Emerging Designer Drugs

The Effects of Drug Abuse on the Human Nervous System

Volumn , Issue , 2013, Pages 575-596

  Nichols, David E ^a   Fantegrossi, William E ^b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cannabinoid; Cathinone; Designer Drugs; Dissociatives; Hallucinogens; MDMA; Phenethylamines; Phenylpiperazines; Psychostimulants; Salvinorin

Indexed keywords

EID: 84903334089     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-418679-8.00019-8     Document Type: Chapter

References (49)

1. Anderson G.M., Braun G., Braun U., Nichols D.E., Shulgin A.T. Absolute configuration and psychotomimetic activity. NIDA Res. Monogr 1978, 8-15.
2. Andreasen M.F., Telving R., Birkler R.I., Schumacher B., Johannsen M. A fatal poisoning involving Bromo-Dragonfly. Forensic Sci. Int. 2009, 183:91-96.
3. Araiza V. New Street Drug Causing Concern among Medics 2012, http://www.wsfa.com/story/16977573/new-street-drug-causng-concern-among-medics.
4. Arbo M.D., Bastos M.L., Carmo H.F. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 2012, 122:174-185.
5. Austin H., Monasterio E. Acute psychosis following ingestion of 'Rapture'. Australas Psychiatry 2004, 12:406-408.
6. Baron M., Elie M., Elie L. An analysis of legal highs: do they contain what it says on the tin?. Drug Test Anal. 2011, 3(9):576-581.
7. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., Rothman R.B. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 2005, 30:550-560.
8. Baumann M.H., Partilla J.S., Lehner K.R., Thorndike E.B., Hoffman A.F., Holy M., Rothman R.B., Goldberg S.R., Lupica C.R., Sitte H.H., Brandt S.D., Tella S.R., Cozzi N.V., Schindler C.W. Powerful cocaine-like actions of 3,4-Methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 2013, 38(4):552-562.
9. Benkelfat C., Murphy D.L., Hill J.L., George D.T., Nutt D., Linnoila M. Ethanollike properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch. Gen. Psychiatry 1991, 48:383.
10. Bowen J.S., Davis G.B., Kearney T.E., Bardin J. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA 1983, 249:1477-1479.
11. Braden M.R., Parrish J.C., Naylor J.C., Nichols D.E. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol. Pharmacol. 2006, 70:1956-1964.
12. Buydens-Branch L., Branchey M., Fergeson P., Hudson J., McKernin C. The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses. Biol. Psychiatry 1997, 41:1071-1086.
13. Campbell H., Cline W., Evans M., Lloyd J., Peck A.W. Proceedings: comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Br. J. Pharmacol. 1972, 44:369-370.
14. Centers for Disease Control and Prevention (CDC) Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb. Mortal Wkly Rep. 2013, 62(6):93-98.
15. Chavkin C., Sud S., Jin W., Stewart J., Zjawiony J.K., Siebert D.J., Toth B.A., Hufeisen S.J., Roth B.L. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J. Pharmacol. Exp. Ther. 2004, 308:1197-1203.
16. Chimalakonda K.C., Seely K.A., Bratton S.M., Brents L.K., Moran C.L., Endres G.W., James L.P., Hollenberg P.F., Prather P.L., Radominska-Pandya A., Moran J.H. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab. Dispos. 2013, 40(11):2174-2184.
17. Conn P.J., Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J. Pharmacol. Exp. Ther. 1987, 242:552-557.
18. Corazza O., Schifano F., Simonato P., Fergus S., Assi S., Stair J., Corkery J., Trincas G., Deluca P., Davey Z., Blaszko U., Demetrovics Z., Moskalewicz J., Enea A., di Melchiorre G., Mervo B., di Furia L., Farre M., Flesland L., Pasinetti M., Pezzolesi C., Pisarska A., Shapiro H., Siemann H., Skutle A., Enea A., di Melchiorre G., Sferrazza E., Torrens M., van der Kreeft P., Zummo D., Scherbaum N. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum. Psychopharmacol. 2012, 27(2):145-149.
19. Elz S., Klass T.H.R., Wamke U., Pertz H.H. Development of highly potent partial agonists and chiral antagonists as tools fo the study of 5-HT2A-receptor mediated functions. Nauyn Schmiedebergs Arch. Pharmacol. 2002, 365(Suppl. 1):R29.
20. Fantegrossi W.E., Winger G., Woods J.H., Woolverton W.L., Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend. 2005, 77:161-168.
21. Fantegrossi W.E., Gannon B.M., Zimmerman S.M., Rice K.C. In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 2013, 38(4):563-573.
22. Frost J.M., Dart M.J., Tietje K.R., Garrison T.R., Grayson G.K., Daza A.V., El-Kouhen O.F., Yao B.B., Hsieh G.C., Pai M., Zhu C.Z., Chandran P., Meyer M.D. Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J. Med. Chem. 2010, 53:295-315.
23. Geller L. Kids Overdosing on New Drug. WWBT NBC12 2012, http://www.nbc12.com/story/16964534/kids-overdosing-on-new-drug.
24. Grotewiel M.S., Chu H., Sanders-Bush E. m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. J. Pharmacol. Exp. Ther. 1994, 271:1122-1126.
25. Heim, R., 2003. Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur Entwicklung eines neen Struktur-Wirkungskonzepts (Ph.D. thesis). Freien Universität Berlin, Berlin.
26. Hermanns-Clausen M., Kneisel S., Szabo B., Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013, 108(3):534-544.
27. McCann U.D., Eligulashvili V., Mertl M., Murphy D.L., Ricaurte G.A. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology (Berl.) 1999, 147:56-65.
28. McLean T.H., Parrish J.C., Braden M.R., Marona-Lewicka D., Gallardo-Godoy A., Nichols D.E. 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J. Med. Chem. 2006, 49:5794-5803.
29. McQuade D., Hudson S., Dargan P.I., Wood D.M. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur. J. Clin. Pharmacol. 2013, 69(3):373-376.
30. Monteiro M.S., Bastos Mde L., Guedes de Pinho P., Carvalho M. Update on 1-benzylpiperazine (BZP) party pills. Arch. Toxicol. 2013, 87(6):929-947.
31. Nichols D.E. Hallucinogens. Pharmacol. Ther. 2004, 101:131-181.
32. Rajasekaran M., Brents L.K., Franks L.N., Moran J.H., Prather P.L. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol. Appl. Pharmacol. 2013, 269(2):100-108.
33. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., Ernsberger P., Rothman R.B. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11934-11939.
34. Roth B.L., Gibbons S., Arunotayanun W., Huang X.P., Setola V., Treble R., Iversen L. The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 2013, 8(3):e59334.
35. Seely K.A., Brents L.K., Radominska-Pandya A., Endres G.W., Keyes G.S., Moran J.H., Prather P.L. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem. Res. Toxicol. 2012, 25(4):825-827.
36. Schoeffter P., Hoyer D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?. Naunyn Schmiedebergs Arch. Pharmacol. 1989, 339:675-683.
37. Sheffler D.J., Roth B.L. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol. Sci. 2003, 24:107-109.
38. Shields J.E., Dargan P.I., Wood D.M., Puchnarewicz M., Davies S., Waring W.S. Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin. Toxicol. 2012, 50(5):438-440.
39. Shulgin A., Shulgin A. PIHKAL: A Chemical Love Story 1991, Transform Press, Berkeley, CA 94701.
40. Siebert D.J. Salvia divinorum and salvinorin A: new pharmacologic findings. J. Ethnopharmacol. 1994, 43:53-56.
41. Tancer M., Johanson C.E. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend. 2003, 72:33-44.
42. Tancer M.E., Johanson C.E. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 2001, 65:97-101.
43. Thornton S.L., Wood C., Friesen M.W., Gerona R.R. Synthetic cannabinoid use associated with acute kidney injury. Clin. Toxicol. 2013, 51(3):189-190.
44. Valdes L.J., Diaz J.L., Paul A.G. Ethnopharmacology of ska Maria Pastora (Salvia divinorum, Epling and Jativa-M.). J. Ethnopharmacol. 1983, 7:287-312.
45. Warrick B.J., Wilson J., Hedge M., Freeman S., Leonard K., Aaron C. Lethal serotonin syndrome after methylone and butylone ingestion. J. Med. Toxicol. 2012, 8:65-68.
46. Wikström M., Thelander G., Dahlgren M., Kronstrand R. An accidental fatal intoxication with methoxetamine. J. Anal. Toxicol. 2013, 37(1):43-46.
47. Winek C.L., Collom W.D., Bricker J.D. A death due to 4-bromo-2,5-dimethoxyamphetamine. Clin. Toxicol. 1981, 18:267-271.
48. Yarosh H.L., Katz E.B., Coop A., Fantegrossi W.E. MDMA-like behavioral effects of N-substituted piperazines in the mouse. Pharmacol. Biochem. Behav. 2007, 88:18-27.
49. Zuba D., Byrska B. Prevalence and co-existence of active components of 'legal highs'. Drug Test Anal 2013, (Epub ahead of print). 10.1002/dta. 1365.